早期乳腺癌的最佳辅助化疗和靶向治疗——细胞周期蛋白依赖性激酶 4 和 6 抑制剂：ASCO 指南快速推荐更新。

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.

机构信息

Dana-Farber Cancer Institute, Boston, MA.

Stanford University School of Medicine, Stanford, CA.

出版信息

J Clin Oncol. 2024 Jun 20;42(18):2233-2235. doi: 10.1200/JCO.24.00886. Epub 2024 May 20.

DOI:10.1200/JCO.24.00886

PMID:38768407

Abstract

摘要

相似文献

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2024 Jun 20;42(18):2233-2235. doi: 10.1200/JCO.24.00886. Epub 2024 May 20.

Systemic Therapy Update on Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2024 Nov;42(31):3751-3752. doi: 10.1200/JCO.23.02128. Epub 2023 Nov 6.

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.

J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13.

Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2024 Sep 1;42(25):3058-3060. doi: 10.1200/JCO-24-01324. Epub 2024 Jul 23.

Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update.

J Clin Oncol. 2022 Jan 20;40(3):307-309. doi: 10.1200/JCO.21.02677. Epub 2021 Dec 8.

Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Sep 1;41(25):4178-4179. doi: 10.1200/JCO.23.01280. Epub 2023 Jul 12.

Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Feb 20;41(6):1318-1320. doi: 10.1200/JCO.22.02807. Epub 2023 Jan 10.

Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Jun 20;41(18):3423-3425. doi: 10.1200/JCO.23.00638. Epub 2023 May 17.

Management of Metastatic Renal Clear Cell Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Nov 20;41(33):5184-5186. doi: 10.1200/JCO.23.01977. Epub 2023 Oct 9.

Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.

J Clin Oncol. 2023 Sep 20;41(27):4430-4432. doi: 10.1200/JCO.23.01261. Epub 2023 Jul 20.

引用本文的文献

Multidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.

Curr Oncol. 2025 Aug 7;32(8):444. doi: 10.3390/curroncol32080444.

Comparing the diagnostic efficacy of [F]FDG PET/CT and [F]FDG PET/MRI in breast cancer recurrence: a systematic review and meta-analysis.

Front Med (Lausanne). 2025 Aug 1;12:1602415. doi: 10.3389/fmed.2025.1602415. eCollection 2025.

Tumor-microenvironment triggered Mn-Gd based nanosystem for breast carcinoma suppression via synergistic radiotherapy and glutathione-depleting along with glucose oxidase combination enhanced Ros storm.

J Nanobiotechnology. 2025 Aug 11;23(1):557. doi: 10.1186/s12951-025-03636-z.

Predicting pathologic ≥N2 disease in women with breast cancer.

NPJ Breast Cancer. 2025 May 22;11(1):46. doi: 10.1038/s41523-025-00757-4.

Survival outcomes in trial defined high-risk hormone receptor-positive/human epidermal growth factor receptor II-negative early breast cancer: impact of adjuvant chemotherapy.

Discov Oncol. 2025 May 16;16(1):783. doi: 10.1007/s12672-025-02601-4.

Extended endocrine therapy use and decision making after breast cancer diagnosis.

J Natl Cancer Inst. 2025 Aug 1;117(8):1573-1582. doi: 10.1093/jnci/djaf076.

Clinician's guide: expert insights on the use of CDK4/6 inhibitors in patients with early breast cancer.

Ther Adv Med Oncol. 2025 Mar 20;17:17588359251326710. doi: 10.1177/17588359251326710. eCollection 2025.

Consensus Guidelines for the Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors in the Management of Hormone Receptor Positive (HR+ve), Her2-ve Early Breast Cancer (EBC).

South Asian J Cancer. 2024 Nov 18;14(1):45-52. doi: 10.1055/s-0044-1791768. eCollection 2025 Jan.

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.

Nat Med. 2025 Feb;31(2):433-441. doi: 10.1038/s41591-024-03414-8. Epub 2025 Jan 21.

ChatGPT's Agreement with the Recommendations from the 18th St. Gallen International Consensus Conference on the Treatment of Early Breast Cancer.

Cancers (Basel). 2024 Dec 13;16(24):4163. doi: 10.3390/cancers16244163.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

早期乳腺癌的最佳辅助化疗和靶向治疗——细胞周期蛋白依赖性激酶 4 和 6 抑制剂：ASCO 指南快速推荐更新。

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献